Blog
RSS FeedPosted by Michael Wonder on 17 Jun 2018
Personalised medicine and pay for performance: should pharmaceutical firms be fully penalised when treatment fails?
17 June 2018 - In this article, we model the behaviour of a pharmaceutical firm that has marketing authorisation for a ...
Posted by Michael Wonder on 16 Jun 2018
Rare disease therapy Crysvita to be barred from NHS
15 June 2018 - Children and young people with X-linked hypophosphataemia are unlikely to get routine access to Kyowa Kirin’s ...
Posted by Michael Wonder on 16 Jun 2018
Adding pertuzumab to existing treatments after surgery for early breast cancer not cost effective, says NICE in draft guidance
15 June 2018 - Women with a type of early breast cancer may not benefit from continuing or starting a ...
Posted by Michael Wonder on 14 Jun 2018
Building synergy between regulatory and HTA agencies beyond processes and procedures—can we effectively align the evidentiary requirements? A survey of stakeholder perceptions
13 June 2018 - The pathway for bringing a new medicine to the market is dependent on two sequential processes: achieving ...
Posted by Michael Wonder on 13 Jun 2018
Janssen’s Tremfya (guselkumab) receives its first two positive Health Technology Assessments in Europe
13 June 2018 - The United Kingdom’s NICE publishes positive guidance for the first selective interleukin 23 inhibitor to treat moderate ...
Posted by Michael Wonder on 13 Jun 2018
Public backs NHS spending increases
13 June 2018 - An “overwhelming majority” of people support increasing spending on health and social care services, indicates a ...
Posted by Michael Wonder on 12 Jun 2018
Who should pay for HTA?
11 June 2018 - Part of the drive for strengthening EU cooperation on health technology assessment is to tackle duplication ...
Posted by Michael Wonder on 12 Jun 2018
The UK National Institute for Health and Care Excellence to undertake a partial review of the Iluvien reimbursement guidance allowing broader availability
11 June 2018 - More patients in England and Wales with chronic DME could benefit from low-dose corticosteroid intravitreal implant that ...
Posted by Michael Wonder on 07 Jun 2018
Pfizer wins appeal against £84m UK fine over epilepsy drug price
7 June 2018 - Tribunal finds competition watchdog was wrong in its market dominance conclusions. ...
Posted by Michael Wonder on 07 Jun 2018
UK health spends lags behind EU peers
7 June 2018 - The amount the UK spends on health falls well behind that invested by European peers such ...
Posted by Michael Wonder on 07 Jun 2018
Takeda pioneers NICE’s new service for economic model review
7 June 2018 - NICE Scientific Advice (NSA) launched a new health economic model review service, PRIMA, in December 2017 and ...
Posted by Michael Wonder on 07 Jun 2018
The ICR responds to decision by NICE not to recommend abiraterone as first-line treatment for advanced prostate cancer
6 June 2018 - The Institute of Cancer Research, London, has expressed disappointment that the prostate cancer drug abiraterone (Zytiga) ...
Posted by Michael Wonder on 06 Jun 2018
Pharma giant Merck is planning for a Brexit supply blackout
6 June 2018 - Drug maker Merck may stockpile six months worth of goods. ...
Posted by Michael Wonder on 06 Jun 2018
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer
6 June 2018 - It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy and prednisone/prednisolone will become routinely ...
Posted by Michael Wonder on 06 Jun 2018
Life-extending lung cancer drug will be more widely available on the NHS after NICE review
6 June 2018 - NICE says more people should be able to freely access pembrolizumab, known as Keytruda, after a new ...